The efficacy seen with ripretinib (Qinlock) in patients with KIT-mutated melanoma was higher than has been previously reported, according to Filip Janku, MD, PhD. Furthermore, the switch-control tyrosine kinase inhibitor (TKI) has elicited durable responses, even in patients who were heavily pretreated, making the drug a powerful tool for this patient population.
Archive | Health Professionals
Ripretinib Demonstrates Impressive Efficacy, Durability in Heavily Pretreated KIT-Mutated Melanoma
Posted in Melanoma News, Health Professionals, Clinical Trials
Larkin Unpacks the Effect of Anti–PD-L1 Therapy on TIL Activity in Melanoma
The role of adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) for patients with melanoma has undergone scrutiny as efforts to unpack the correlation between the duration of prior immunotherapy and efficacy outcomes.
Posted in Melanoma News, Health Professionals, Of Interest
Darovasertib/Crizotinib Shows Early Efficacy in Metastatic Uveal Melanoma
Darovasertib and crizotinib demonstrated promising efficacy and tolerable safety in patients with metastatic uveal melanoma, according to preliminary results of a phase 1/2 trial announced in a press release from IDEAYA Biosciences.
Posted in Melanoma News, Health Professionals, Clinical Trials
Boosting anti-cancer action by driving up immunity at tumor site
Driving up the immune response at the site of a cancer tumor with nanotechnology may help enhance immunotherapy treatments in advanced stages of the disease, new research in mice suggests.
Posted in Melanoma News, Health Professionals, Of Interest
 |
 |
 |
 |
